What type of study is this?

December 8, 2025Korean Journal of MedicineOpen Access

Optimal Choice of Biologics and Small Molecules for Treating Women of Childbearing Age with Inflammatory Bowel Disease

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis highlights safety of biologics like anti-TNF for IBD in pregnancy, suggesting caution for small molecules.

Maternal and fetal safety is paramount, as biologics like anti-TNF agents are deemed safe during pregnancy and lactation.
Current evidence indicates that small molecules may pose risks, including preterm birth and congenital malformations, necessitating their avoidance.
Treatment decisions for women of childbearing age with IBD require individualization based on evidence and patient preferences.
Existing guidelines recommend discontinuing small molecules before conception and avoiding them during pregnancy and breastfeeding.

Eun Mi Song (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Korean Journal of MedicineOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis highlights safety of biologics like anti-TNF for IBD in pregnancy, suggesting caution for small molecules.

Maternal and fetal safety is paramount, as biologics like anti-TNF agents are deemed safe during pregnancy and lactation.
Current evidence indicates that small molecules may pose risks, including preterm birth and congenital malformations, necessitating their avoidance.
Treatment decisions for women of childbearing age with IBD require individualization based on evidence and patient preferences.
Existing guidelines recommend discontinuing small molecules before conception and avoiding them during pregnancy and breastfeeding.

Eun Mi Song (2025) studied this question.

View Full Paper

Ask AI

Bookmark